Ipca Laboratories Ltd. — Investor Relations & Filings
Ipca Laboratories Ltd. is a vertically integrated entity focused on the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs) and finished dosage formulations. The company serves a global market, distributing products to over 120 countries. Its therapeutic portfolio covers rheumatology, antimalarials, cardiology, gastroenterology, pain management, and diabetology. Notably, it is a leading global producer of antimalarial agents such as Chloroquine and Hydroxychloroquine. Operations are supported by multiple manufacturing sites that adhere to international regulatory standards, alongside dedicated research and development centers. The company’s strategic emphasis on backward integration allows for optimized production processes and the delivery of high-quality medicinal solutions across diverse healthcare sectors.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| Disclosure under SEBI Takeover Regulations | 2026-04-10 | English | |
| Certificate under SEBI (Depositories and Participants) Regulations, 2018 | 2026-04-08 | English | |
| Copy of Newspaper Publication | 2026-04-02 | English | |
| Trading Window | 2026-03-16 | English | |
| Analysts/Institutional Investor Meet/Con. Call Updates | 2026-02-18 | English | |
| Analysts/Institutional Investor Meet/Con. Call Updates | 2026-02-16 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 42201504 | Disclosure under SEBI Takeover Regulations | 2026-04-10 | English | ||
| 42185624 | Certificate under SEBI (Depositories and Participants) Regulations, 2018 | 2026-04-08 | English | ||
| 42168170 | Copy of Newspaper Publication | 2026-04-02 | English | ||
| 42188833 | Trading Window | 2026-03-16 | English | ||
| 42176520 | Analysts/Institutional Investor Meet/Con. Call Updates | 2026-02-18 | English | ||
| 42193964 | Analysts/Institutional Investor Meet/Con. Call Updates | 2026-02-16 | English | ||
| 42201021 | Copy of Newspaper Publication | 2026-02-16 | English | ||
| 42248926 | Outcome of Board Meeting | 2026-02-13 | English | ||
| 42254278 | General Updates | 2026-02-09 | English | ||
| 42274342 | General Updates | 2026-02-07 | English | ||
| 42284402 | Analysts/Institutional Investor Meet/Con. Call Updates | 2026-02-06 | English | ||
| 43885162 | Board Meeting — Board Meeting Intimation | 2026-01-22 | English | ||
| 43885178 | Board Meeting — Financial Results | 2026-01-22 | English | ||
| 42182149 | Updates | 2026-01-21 | English | ||
| 42222185 | Updates | 2026-01-13 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
BiomX Inc.
Clinical-stage company developing phage therapies to target…
|
PHGE | US | Manufacturing |
|
BIONEERCORPORATION
Develops and manufactures molecular biology products for re…
|
064550 | KR | Manufacturing |
|
BioNTech SE
Biotechnology company developing immunotherapies for cancer…
|
BNTX | DE | Manufacturing |
|
BioNxt Solutions Inc.
Clinical-stage developer of next-generation drug formulatio…
|
BNXT | CA | Manufacturing |
|
Biophage Pharma Inc.
Developing innovative phage-based therapies for antibiotic-…
|
BIPMF | CA | Manufacturing |
|
BioPorto
An in vitro diagnostics company specializing in biomarkers …
|
BIOPOR | DK | Manufacturing |
|
BIO-RAD LABORATORIES, INC.
Develops and manufactures products for life science and cli…
|
BIO | US | Manufacturing |
|
Biosergen AB
Develops drugs to treat severe and resistant invasive funga…
|
BIOSGN | SE | Manufacturing |
|
Biosino Bio-Technology and Science Incorporation
Major high-tech manufacturer of in-vitro diagnostic (IVD) p…
|
8247 | HK | Manufacturing |
|
Bio Solution Co.,Ltd.
Develops cell therapies, human tissue models, and bio-labor…
|
086820 | KR | Manufacturing |
Ipca Laboratories Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/61700/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=61700 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=61700 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=61700 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 61700}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Ipca Laboratories Ltd. (id: 61700)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.